Ying Li1, Mingmei Du2, Liang-An Chen1, Yunxi Liu2, Zhixin Liang3. 1. Department of Respiratory Medicine, Chinese PLA General Hospital, Fuxing Road No. 28, Beijing, 100853, China. 2. Department of Infection Management and Disease Control, Chinese PLA General Hospital, Beijing, 100853, China. 3. Department of Respiratory Medicine, Chinese PLA General Hospital, Fuxing Road No. 28, Beijing, 100853, China. liangzhixin301@163.com.
Abstract
OBJECTIVES: To investigate the distribution of Candida spp., predictors of mortality, and effects of therapeutic measures on outcomes of nosocomial bloodstream infection (BSI) due to Candida spp. METHODS: This retrospective, population-based study enrolled adult patients with Candida nosocomial BSI from January 2010 to December 2014 in one tertiary care hospital. The demographics, comorbidities, species distribution, risk factors, and effects of antifungal treatment were assessed. RESULTS: In total, 190 episodes of Candida BSI were identified. The most prevalent species was C. albicans (38.9 %), followed by C. parapsilosis (23.2 %) and C. tropicalis (20.5 %). In vitro susceptibility testing showed that 88.9 % of Candida isolates were susceptible to fluconazole. The 30-day hospital mortality was 27.9 %, while the early mortality (within 7 days) was 16.3 %. In a multivariate regression analysis, the Acute Physiology and Chronic Health Evaluation II score [odds ratio (OR) 1.23; 95 % confidence interval (CI) 1.080-1.390; P = 0.002] and severe sepsis or septic shock (OR 15.35; 95 % CI 2.391-98.502; P = 0.004) were independently correlated with early mortality. Severe sepsis or septic shock (OR 24.75; 95 % CI 5.099-120.162; P < 0.001) was an independent risk factor for 30-day mortality, while proven catheter-related candidemia (OR 0.16; 95 % CI 0.031-0.810; P = 0.027) was a positive factor for 30-day mortality. Early central venous catheter removal and adequate antifungal treatment were closely related to decreased mortality in patients with primary candidemia. CONCLUSION: The proportion of candidemia caused by C. albicans was lower than that caused by non-albicans species. The severity of illness influenced early mortality, and the origin of the central venous catheter remarkably affected 30-day mortality.
OBJECTIVES: To investigate the distribution of Candida spp., predictors of mortality, and effects of therapeutic measures on outcomes of nosocomial bloodstream infection (BSI) due to Candida spp. METHODS: This retrospective, population-based study enrolled adult patients with Candida nosocomial BSI from January 2010 to December 2014 in one tertiary care hospital. The demographics, comorbidities, species distribution, risk factors, and effects of antifungal treatment were assessed. RESULTS: In total, 190 episodes of Candida BSI were identified. The most prevalent species was C. albicans (38.9 %), followed by C. parapsilosis (23.2 %) and C. tropicalis (20.5 %). In vitro susceptibility testing showed that 88.9 % of Candida isolates were susceptible to fluconazole. The 30-day hospital mortality was 27.9 %, while the early mortality (within 7 days) was 16.3 %. In a multivariate regression analysis, the Acute Physiology and Chronic Health Evaluation II score [odds ratio (OR) 1.23; 95 % confidence interval (CI) 1.080-1.390; P = 0.002] and severe sepsis or septic shock (OR 15.35; 95 % CI 2.391-98.502; P = 0.004) were independently correlated with early mortality. Severe sepsis or septic shock (OR 24.75; 95 % CI 5.099-120.162; P < 0.001) was an independent risk factor for 30-day mortality, while proven catheter-related candidemia (OR 0.16; 95 % CI 0.031-0.810; P = 0.027) was a positive factor for 30-day mortality. Early central venous catheter removal and adequate antifungal treatment were closely related to decreased mortality in patients with primary candidemia. CONCLUSION: The proportion of candidemia caused by C. albicans was lower than that caused by non-albicans species. The severity of illness influenced early mortality, and the origin of the central venous catheter remarkably affected 30-day mortality.
Authors: Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden Journal: Clin Infect Dis Date: 2006-05-16 Impact factor: 9.079
Authors: O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann Journal: Clin Microbiol Infect Date: 2012-12 Impact factor: 8.067
Authors: M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer Journal: J Clin Microbiol Date: 2001-09 Impact factor: 5.948
Authors: Abdul Hakeem O Al Thaqafi; Fayssal M Farahat; Maher I Al Harbi; Abdul Fattah W Al Amri; John R Perfect Journal: Int J Infect Dis Date: 2014-01-25 Impact factor: 3.623
Authors: Matteo Bassetti; Maria Merelli; Elda Righi; Ana Diaz-Martin; Eva Maria Rosello; Roberto Luzzati; Anna Parra; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Mario Tumbarello Journal: J Clin Microbiol Date: 2013-10-09 Impact factor: 5.948
Authors: José Garnacho-Montero; Ana Díaz-Martín; Emilio García-Cabrera; Maite Ruiz Pérez de Pipaón; Clara Hernández-Caballero; José A Lepe-Jiménez Journal: J Antimicrob Chemother Date: 2012-09-03 Impact factor: 5.790
Authors: Hilmar Wisplinghoff; Jenny Ebbers; Lea Geurtz; Danuta Stefanik; Yvette Major; Michael B Edmond; Richard P Wenzel; Harald Seifert Journal: Int J Antimicrob Agents Date: 2013-10-12 Impact factor: 5.283
Authors: Min Chen; Yuan Xu; Nan Hong; Yali Yang; Wenzhi Lei; Lin Du; Jingjun Zhao; Xia Lei; Lin Xiong; Langqi Cai; Hui Xu; Weihua Pan; Wanqing Liao Journal: Front Med Date: 2018-01-11 Impact factor: 4.592